TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
States have an important role in ensuring food safety and healthy food practices.
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated
